المؤلفون: Boscolo Bielo L; Division of New Drugs and Early Drug Development for Innovative Therapies, European Institute of Oncology, IRCCS, Milan, Italy; Department of Oncology and Hemato-Oncology, University of Milan, Milan, Italy., Trapani D; Division of New Drugs and Early Drug Development for Innovative Therapies, European Institute of Oncology, IRCCS, Milan, Italy; Department of Oncology and Hemato-Oncology, University of Milan, Milan, Italy., Nicolò E; Department of Medicine, Division of Hematology-Oncology, Weill Cornell Medicine, New York, NY, USA., Valenza C; Division of New Drugs and Early Drug Development for Innovative Therapies, European Institute of Oncology, IRCCS, Milan, Italy; Department of Oncology and Hemato-Oncology, University of Milan, Milan, Italy., Guidi L; Division of New Drugs and Early Drug Development for Innovative Therapies, European Institute of Oncology, IRCCS, Milan, Italy; Department of Oncology and Hemato-Oncology, University of Milan, Milan, Italy., Belli C; Division of New Drugs and Early Drug Development for Innovative Therapies, European Institute of Oncology, IRCCS, Milan, Italy., Kotteas E; Oncology Unit, Sotiria General Hospital, 3rd Dept of Internal Medicine, Athens School of Medicine, Greece., Marra A; Division of New Drugs and Early Drug Development for Innovative Therapies, European Institute of Oncology, IRCCS, Milan, Italy., Prat A; Department of Medical Oncology and Translational Genomics and Targeted Therapies in Solid Tumors, August Pi i Sunyer Biomedical Research Institute (IDIBAPS), Barcelona, Spain; Faculty of Medicine and Health Sciences, University of Barcelona, Spain., Fusco N; Department of Oncology and Hemato-Oncology, University of Milan, Milan, Italy; Division of Pathology, IEO, European Institute of Oncology IRCCS, Milan, Italy., Criscitiello C; Division of New Drugs and Early Drug Development for Innovative Therapies, European Institute of Oncology, IRCCS, Milan, Italy; Department of Oncology and Hemato-Oncology, University of Milan, Milan, Italy., Burstein HJ; Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA; Breast Oncology Program, Dana-Farber Brigham Cancer Center, Boston, MA, USA; Harvard Medical School, Boston, MA, USA., Curigliano G; Division of New Drugs and Early Drug Development for Innovative Therapies, European Institute of Oncology, IRCCS, Milan, Italy; Department of Oncology and Hemato-Oncology, University of Milan, Milan, Italy. Electronic address: giuseppe.curigliano@ieo.it.

المصدر: Cancer treatment reviews [Cancer Treat Rev] 2024 Jul; Vol. 128, pp. 102761. Date of Electronic Publication: 2024 May 16.

نوع المنشور: Journal Article; Review

بيانات الدورية: Publisher: Elsevier Country of Publication: Netherlands NLM ID: 7502030 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1532-1967 (Electronic) Linking ISSN: 03057372 NLM ISO Abbreviation: Cancer Treat Rev Subsets: MEDLINE

مواضيع طبية MeSH: Receptor, ErbB-2*/metabolism , Breast Neoplasms*/drug therapy , Breast Neoplasms*/pathology , Breast Neoplasms*/metabolism, Humans ; Female ; Receptors, Estrogen/metabolism ; Receptors, Progesterone/metabolism ; Molecular Targeted Therapy/methods ; Drug Resistance, Neoplasm

المؤلفون: Tarantino P; Medical Oncology, Dana-Farber Cancer Institute, Boston, MA.; Breast Oncology Program, Dana-Farber Brigham Cancer Center, Boston, MA.; Harvard Medical School, Boston, MA.; Department of Oncology and Hemato-Oncology, University of Milan, Milan, Italy., Tayob N; Harvard Medical School, Boston, MA.; Division of Data Science, Dana-Farber Cancer Institute, Boston, MA., Villacampa G; SOLTI Breast Cancer Research Group, Barcelona, Spain.; Oncology Data Science Vall d'Hebron Institute of Oncology, Barcelona, Spain., Dang C; Memorial Sloan Kettering Cancer Center, New York, NY., Yardley DA; Sarah Cannon Research Institute and Tennessee Oncology, Nashville, TN., Isakoff SJ; Harvard Medical School, Boston, MA.; Massachusetts General Hospital, Boston, MA., Valero V; MD Anderson Cancer Center, Houston, TX., Faggen M; Medical Oncology, Dana-Farber Cancer Institute, Boston, MA., Mulvey T; Harvard Medical School, Boston, MA.; Massachusetts General Hospital, Boston, MA., Bose R; Washington University School of Medicine, St Louis, MO., Weckstein D; New Hampshire Oncology Hematology, Manchester, NH., Wolff AC; Johns Hopkins Sidney Kimmel Cancer Center, Washington, DC., Reeder-Hayes K; University of North Carolina Lineberger Comprehensive Cancer Center, Chapel Hill, NC., Rugo HS; University of California, San Francisco, CA., Ramaswamy B; Ohio State University Comprehensive Cancer Center, Columbus, OH., Zuckerman D; St Luke's Mountain States Tumor Institute, Boise, ID., Hart L; Wake Forest Baptist Health, Winston-Salem, NC., Gadi VK; University of Illinois Cancer Center, Chicago, IL., Constantine M; Medical Oncology, Dana-Farber Cancer Institute, Boston, MA., Cheng K; North Shore-LIJ Cancer Institute, Lake Success, NY., Garrett AM; Northern Light Cancer Care, Brewer, ME., Marcom PK; Duke University School of Medicine, Durham, NC., Albain K; Loyola University Medical Center, Maywood, IL., DeFusco P; Hartford Healthcare Cancer Institute, Hartford, CT., Tung N; Harvard Medical School, Boston, MA.; Beth Israel Deaconess Medical Center, Boston, MA., Ardman B; Lowell General Hospital, Lowell, MA., Nanda R; UChicago Medicine, Chicago, IL., Jankowitz RC; Perelman Center for Advanced Medicine, Philadelphia, PA., Rimawi M; Dan L. Duncan Comprehensive Cancer Center, Baylor College of Medicine, Houston, TX., Abramson V; Vanderbilt-Ingram Cancer Center, Nashville, TN., Pohlmann PR; MD Anderson Cancer Center, Houston, TX.; Lombardi Comprehensive Cancer Center, Georgetown University Medical Center, Washington, DC., Van Poznak C; Rogel Cancer Center, University of Michigan, Ann Arbor, MI., Forero-Torres A; Kirklin UAB Hematology Oncology, Birmingham, AL., Liu MC; Natera, Inc, Austin, TX., Ruddy KJ; Mayo Clinic, Rochester, NY., Waks AG; Medical Oncology, Dana-Farber Cancer Institute, Boston, MA.; Breast Oncology Program, Dana-Farber Brigham Cancer Center, Boston, MA.; Harvard Medical School, Boston, MA., DeMeo M; Breast Oncology Program, Dana-Farber Brigham Cancer Center, Boston, MA., Burstein HJ; Medical Oncology, Dana-Farber Cancer Institute, Boston, MA.; Breast Oncology Program, Dana-Farber Brigham Cancer Center, Boston, MA.; Harvard Medical School, Boston, MA., Partridge AH; Medical Oncology, Dana-Farber Cancer Institute, Boston, MA.; Breast Oncology Program, Dana-Farber Brigham Cancer Center, Boston, MA.; Harvard Medical School, Boston, MA., Dell'Orto P; IEO European Institute of Oncology, IRCCS, Milan, Italy., Russo L; IEO European Institute of Oncology, IRCCS, Milan, Italy., Krause E; PathAI, Boston, MA., Newhouse DJ; NanoString Technologies, Inc, Boston, MA., Kurt BB; Breast Oncology Program, Dana-Farber Brigham Cancer Center, Boston, MA., Mittendorf EA; Breast Oncology Program, Dana-Farber Brigham Cancer Center, Boston, MA.; Harvard Medical School, Boston, MA.; Division of Breast Surgery, Department of Surgery, Brigham and Women's Hospital, Boston, MA., Schneider B; Indiana University School of Medicine, Indianapolis, IN., Prat A; SOLTI Breast Cancer Research Group, Barcelona, Spain.; Translational Genomics and Targeted Therapeutics in Solid Tumors, August Pi i Sunyer Biomedical Research Institute (IDIBAPS), Barcelona, Spain.; Department of Medical Oncology, Hospital Clinic of Barcelona, Barcelona, Spain., Winer EP; Medical Oncology, Dana-Farber Cancer Institute, Boston, MA.; Breast Oncology Program, Dana-Farber Brigham Cancer Center, Boston, MA.; Harvard Medical School, Boston, MA.; Yale Cancer Center, New Haven, CT., Krop IE; Medical Oncology, Dana-Farber Cancer Institute, Boston, MA.; Breast Oncology Program, Dana-Farber Brigham Cancer Center, Boston, MA.; Harvard Medical School, Boston, MA.; Yale Cancer Center, New Haven, CT., Tolaney SM; Medical Oncology, Dana-Farber Cancer Institute, Boston, MA.; Breast Oncology Program, Dana-Farber Brigham Cancer Center, Boston, MA.; Harvard Medical School, Boston, MA.

مؤلفون مشاركون: Consortium of the TBCRC Translational Investigators, TBCRC Translational Investigators

المصدر: Journal of clinical oncology : official journal of the American Society of Clinical Oncology [J Clin Oncol] 2024 Jun 27, pp. JCO2302170. Date of Electronic Publication: 2024 Jun 27.

نوع المنشور: Journal Article

بيانات الدورية: Publisher: American Society of Clinical Oncology Country of Publication: United States NLM ID: 8309333 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1527-7755 (Electronic) Linking ISSN: 0732183X NLM ISO Abbreviation: J Clin Oncol Subsets: MEDLINE

المؤلفون: Schmiester L; University of Oslo, Oslo, Norway., Brasó-Maristany F; August Pi i Sunyer Biomedical Research Institute (IDIBAPS), Barcelona, Spain., González-Farré B; Hospital Clinic of Barcelona, Barcelona, Spain., Pascual T; Solti, Barcelona, Cataluña, Spain., Gavilá J; Fundación Instituto Valenciano de Oncología, Valencia, Spain., Tekpli X; Oslo University Hospital, Oslo, Norway., Geisler J; Akershus University Hospital & Institute of Clinical Medicine, University of Oslo, Norway, Lorenskog, Norway., Kristensen VN; Akershus University Hospital, Oslo, Norway., Frigessi A; University of Oslo, Oslo, Norway., Prat A; Hospital Clinic de Barcelona, Barcelona, Spain., Köhn-Luque A; University of Oslo, Oslo, Norway.

المصدر: Clinical cancer research : an official journal of the American Association for Cancer Research [Clin Cancer Res] 2024 Jun 26. Date of Electronic Publication: 2024 Jun 26.

نوع المنشور: Journal Article

بيانات الدورية: Publisher: The Association Country of Publication: United States NLM ID: 9502500 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1557-3265 (Electronic) Linking ISSN: 10780432 NLM ISO Abbreviation: Clin Cancer Res Subsets: MEDLINE

المؤلفون: Garrido C; Daiichi Sankyo, Inc, Basking Ridge, NJ, USA. rgarrido@dsi.com., Manoogian M; Roche Tissue Diagnostics, Tucson, AZ, USA. melissa.manoogian@roche.com., Ghambire D; Daiichi Sankyo, Inc, Basking Ridge, NJ, USA., Lucas S; Roche Tissue Diagnostics, Tucson, AZ, USA., Karnoub M; Daiichi Sankyo, Inc, Basking Ridge, NJ, USA., Olson MT; Roche Tissue Diagnostics, Tucson, AZ, USA., Hicks DG; The University of Rochester Medical Center, Rochester, USA., Tozbikian G; The Ohio State University Wexner Medical Center, Columbus, OH, USA., Prat A; Department of Medical Oncology, IDIBAPS, University of Barcelona, Barcelona, Spain., Ueno NT; University of Hawai'i Cancer Center, Honolulu, HI, USA., Modi S; Memorial Sloan Kettering Cancer Center, New York, NY, USA., Feng W; Daiichi Sankyo, Inc, Basking Ridge, NJ, USA., Pugh J; Roche Tissue Diagnostics, Tucson, AZ, USA., Hsu C; Daiichi Sankyo, Inc, Basking Ridge, NJ, USA., Tsurutani J; The Innovative Center of Translational Research and Clinical Science for Cancer Therapy, Showa University Hospital, Tokyo, Japan., Cameron D; University of Edinburgh Cancer Centre, Institute of Genetics and Cancer, Edinburgh, UK., Harbeck N; Breast Center, Depart of OB&GYN and CCC Munich, LMU University Hospital, Munich, Germany., Fang Q; Roche Tissue Diagnostics, Tucson, AZ, USA., Khambata-Ford S; Daiichi Sankyo, Inc, Basking Ridge, NJ, USA., Liu X; Roche Tissue Diagnostics, Tucson, AZ, USA., Inge LJ; Roche Tissue Diagnostics, Tucson, AZ, USA., Vitazka P; Daiichi Sankyo, Inc, Basking Ridge, NJ, USA.; Teva Pharmaceuticals, Parsippany, NJ, USA.

المصدر: Virchows Archiv : an international journal of pathology [Virchows Arch] 2024 Jun; Vol. 484 (6), pp. 1005-1014. Date of Electronic Publication: 2023 Oct 20.

نوع المنشور: Journal Article; Validation Study

بيانات الدورية: Publisher: Springer International Country of Publication: Germany NLM ID: 9423843 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1432-2307 (Electronic) Linking ISSN: 09456317 NLM ISO Abbreviation: Virchows Arch Subsets: MEDLINE

مواضيع طبية MeSH: Breast Neoplasms*/drug therapy , Breast Neoplasms*/pathology , Breast Neoplasms*/metabolism , Trastuzumab*/therapeutic use , Receptor, ErbB-2*/analysis , Receptor, ErbB-2*/metabolism , Immunoconjugates*/therapeutic use , Camptothecin*/analogs & derivatives , Camptothecin*/therapeutic use, Humans ; Female ; Reproducibility of Results ; Antineoplastic Agents, Immunological/therapeutic use ; Biomarkers, Tumor/analysis ; Biomarkers, Tumor/metabolism ; Immunohistochemistry/methods ; Antibodies, Monoclonal, Humanized/therapeutic use ; Animals

المؤلفون: Cardoso F; Breast Unit, Champalimaud Clinical Centre/Champalimaud Foundation, and ABC Global Alliance, Lisbon, Portugal. Electronic address: fatimacardoso@fundacaochampalimaud.pt., Paluch-Shimon S; Hadassah University Hospital - Sharett Institute of Oncology, Jerusalem, Israel., Schumacher-Wulf E; Mamma Mia, Kronberg, Germany., Matos L; Breast Unit, Champalimaud Clinical Centre/Champalimaud Foundation, Lisbon, Portugal., Gelmon K; BC Cancer Agency, Department of Medical Oncology, Vancouver, Canada., Aapro MS; Cancer Center, Clinique de Genolier, Genolier, Switzerland., Bajpai J; Tata Memorial Centre, HBNI, Mumbai, India., Barrios CH; Latin American Cooperative Oncology Group (LACOG), Grupo Oncoclínicas, Porto Alegre, Brazil., Bergh J; Department of Oncology-Pathology, Karolinska Institute, Stockholm, Sweden., Bergsten-Nordström E; Europa Donna - the European Breast Cancer Coalition, Norrkoping, Sweden., Biganzoli L; Department of Oncology, Hospital of Prato - Azienda USL Toscana Centro Prato, Italy and European Society of Breast Cancer Specialists (EUSOMA), Italy., Cardoso MJ; Breast Unit, Champalimaud Clinical Centre/Champalimaud Foundation and Lisbon University, Faculty of Medicine, Lisbon, Portugal., Carey LA; UNC Lineberger Comprehensive Cancer Center, Chapel Hill, USA., Mac Gregor MC; Health Services Research, Breast Medical Oncology, The University of Texas MD Anderson Cancer Center, USA and American Society of Clinical Oncology (ASCO), Houston, USA., Chidebe R; Project PINKBLUE, Abuja, Nigeria., Cortés J; International Breast Cancer Center (IBCC), Madrid and Barcelona, Spain., Curigliano G; European Institute of Oncology, IRCCS, Milano, Italy; Department of Oncology and Hemato-Oncology, University of Milano, Milano, Italy., Dent RA; National Cancer Center Singapore, Singapore, Singapore., El Saghir NS; NK Basile Cancer Institute, American University of Beirut Medical Center, Beirut, Lebanon., Eniu A; Hôpital Riviera-Chablais, Vaud-Valais Rennaz, Switzerland and European School of Oncology (ESO), United Kingdom., Fallowfield L; Brighton & Sussex Medical School, University of Sussex, Brighton, United Kingdom., Francis PA; Department of Medical Oncology, Peter MacCallum Cancer Centre, Sir Peter MacCallum Department of Oncology, University of Melbourne, Australia., Franco Millan SX; CTIC, Cancer Treatment and Research Center, Bogotá, Colombia., Gilchrist J; Macquarie University, Sydney, Australia., Gligorov J; Department of Medical Oncology, Cancer Est APHP Tenon, University Paris VI, Nice/St Paul Guidelines, Paris, France., Gradishar WJ; Northwestern Medicine, Illinois, USA and National Comprehensive Cancer Network (NCCN), USA., Haidinger R; Brustkrebs Deutschland e.V., Munich, Germany., Harbeck N; Breast Centre, University of Munich, Munich and Arbeitsgemeinschaft Gynäkologische Onkologie, Kommission Mamma (AGO Guidelines), Germany., Hu X; Department of Medical Oncology, Fudan University Shanghai Cancer Center, Shanghai, China., Kaur R; Breast Cancer Welfare Association, Petaling Jaya, Malaysia., Kiely B; NHMRC Clinical Trials Centre, Sydney Medical School, Sydney, Australia., Kim SB; Asan Medical Centre, Department of Oncology, Seoul, South Korea., Koppikar S; Lilavati Hospital and Research Centre, Bombay Hospital Institute of Medical Sciences, Asian Cancer Institute, Mumbai, India., Kuper-Hommel MJJ; Te Whatu Ora Waikato, Midland Regional Cancer Centre, NZ ABC Guidelines, Hamilton, New Zealand., Lecouvet FE; Department of Radiology, Institut Roi Albert II and Institut de Recherche Expérimentale et Clinique (IREC), Cliniques Universitaires Saint Luc, Université Catholique de Louvain, Brussels, Belgium., Mason G; Inflammatory Breast Cancer Research Foundation, West Lafayette, USA., Mertz SA; MBC US Alliance and Metastatic Breast Cancer Network US, Inverness, USA., Mueller V; University Medical Center Hamburg-Eppendorf, Hamburg and Arbeitsgemeinschaft Gynäkologische Onkologie, Kommission Mamma (AGO Guidelines), Germany., Myerson C; Breast Cancer Now, London, United Kingdom., Neciosup S; Department of Medical Oncology, National Institute of Neoplastic Diseases, Lima, ABC Latin America Guidelines, Peru., Offersen BV; Department of Oncology, Aarhus University Hospital, Aarhus, European Society for Radiotherapy and Oncology (ESTRO), Denmark., Ohno S; Breast Oncology Centre, Cancer Institute Hospital, Tokyo, Japan., Pagani O; Hôpital Riviera-Chablais, Vaud-Valais Rennaz, Switzerland., Partridge AH; Dana-Farber Cancer Institute, Department of Medical Oncology and Division of Breast Oncology, Boston, USA and American Society of Clinical Oncology (ASCO), USA., Penault-Llorca F; Centre Jean Perrin, Université Clermont Auvergne, INSERM, U1240 Imagerie Moléculaire et Stratégies Théranostiques, F-63000, Clermont Ferrand, Nice/St Paul Guidelines, France., Prat A; Hospital Clínic of Barcelona, University of Barcelona, Barcelona, Spain., Rugo HS; Breast Oncology and Clinical Trials Education, UCSF Helen Diller Family Comprehensive Cancer Center, San Francisco, USA., Senkus E; Department of Oncology and Radiotherapy, Medical University of Gdansk, Gdansk, Poland., Sledge GW; Division of Oncology, Stanford School of Medicine, Stanford, USA., Swain SM; Georgetown University Lombardi Comprehensive Cancer Center and MedStar Health, Washington DC, USA., Thomssen C; Department of Gynaecology, Martin-Luther-University Halle-Wittenberg, Halle (Saale) and Arbeitsgemeinschaft Gynäkologische Onkologie, Kommission Mamma (AGO Guidelines), Germany., Vorobiof DA; Belong.Life, New York, USA., Vuylsteke P; University of Botswana, Gaborone, Botswana and CHU UCL Namur Hospital, UCLouvain, Belgium., Wiseman T; The Royal Marsden NHS Foundation Trust, University of Southampton, United Kingdom and European Oncology Nursing Society (EONS), United Kingdom., Xu B; Department of Medical Oncology, Cancer Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing, China., Costa A; European School of Oncology, Milan, Italy and Bellinzona, Switzerland., Norton L; Breast Cancer Programs, Memorial Sloan-Kettering Cancer Centre, New York, USA., Winer EP; Yale Cancer Center, Yale University School of Medicine, New Haven, CT, USA.

المصدر: Breast (Edinburgh, Scotland) [Breast] 2024 May 28; Vol. 76, pp. 103756. Date of Electronic Publication: 2024 May 28.

نوع المنشور: Journal Article

بيانات الدورية: Publisher: Elsevier Country of Publication: Netherlands NLM ID: 9213011 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1532-3080 (Electronic) Linking ISSN: 09609776 NLM ISO Abbreviation: Breast Subsets: MEDLINE

المؤلفون: Conte P; San Camillo Hospital IRCCS, Venezia, Italy., Ciruelos E; Hospital Universitario 12 de Octubre, Madrid, Spain; Centro Integral Oncológico Clara Campal HM (CIOCC), Madrid, Spain; SOLTI Breast Cancer Research Group, Barcelona, Spain., Curigliano G; Division of Early Drug Development for Innovative Therapy, European Institute of Oncology (IEO), IRCCS, Milan, Italy; Department of Oncology and Haematology, University of Milano, Milano, Italy., De Laurentiis M; National Cancer Institute, IRCCS Fondazione G. Pascale, Napoli, Italy., Del Mastro L; Department of Medical Oncology, Clinica di Oncologia Medica, IRCCS Ospedale Policlinico San Martino, Genova, Italy; Department of Internal Medicine and Medical Specialties, School of Medicine, University of Genova, Genova, Italy., Gennari A; Medical Oncology, Department of Translational Medicine, University of Eastern Piedmont, Novara, Italy., Llombart A; Oncology Department, Hospital Arnau de Vilanova, Fundación para el Fomento de la Investigación Sanitaria y Biomédica de la Comunitat Valenciana (FISABIO), Valencia, Spain; Oncology Department, Universidad Católica, Valencia 46900 Spain., Martìn M; Gregorio Marañon Health Research Institute, Universidad Complutense, Madrid, Spain., Poggio F; Department of Medical Oncology, Clinica di Oncologia Medica, IRCCS Ospedale Policlinico San Martino, Genova, Italy. Electronic address: francescabenedetta.poggio@hsanmartino.it., Prat A; Translational Genomics and Targeted Therapies in Solid Tumors, August Pi i Sunyer Biomedical Research Institute (IDIBAPS), Barcelona, Spain; Department of Medical Oncology, Hospital Clinic of Barcelona, Spain; SOLTI Cooperative Group, Barcelona, Spain; Department of Medicine, University of Barcelona, Barcelona, Spain; Institute of Oncology (IOB)-Hospital Quirónsalud, Barcelona, Spain., Puglisi F; Department of Medicine (DAME), University of Udine, Udine, Italy; Department of Medical Oncology, Centro di Riferimento Oncologico di Aviano (CRO) IRCCS, Aviano (PN), Italy., Saura C; Medical Oncology Service, Breast Cancer Unit, Vall d'Hebron Institute of Oncology (VHIO), Barcelona, Spain.

المصدر: Breast (Edinburgh, Scotland) [Breast] 2024 May 16; Vol. 76, pp. 103742. Date of Electronic Publication: 2024 May 16.

نوع المنشور: Journal Article

بيانات الدورية: Publisher: Elsevier Country of Publication: Netherlands NLM ID: 9213011 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1532-3080 (Electronic) Linking ISSN: 09609776 NLM ISO Abbreviation: Breast Subsets: MEDLINE

المؤلفون: Schettini F; Translational Genomics and Targeted Therapies in Solid Tumors group, August Pi i Sunyer Biomedical Research Institute (IDIBAPS), Barcelona, Spain.; Department of Medical Oncology, Hospital Clinic of Barcelona, Barcelona, Spain.; Department of Medicine and Health Sciences, University of Barcelona, Barcelona, Spain., Blondeaux E; U.O. Epidemiologia Clinica, IRCCS Ospedale Policlinico San Martino, Genova, Italy., Molinelli C; Department of Internal Medicine and Medical Specialties (DiMI), School of Medicine, University of Genova, Genova, Italy.; Department of Medical Oncology, U.O. Clinica di Oncologia Medica, IRCCS Ospedale Policlinico San Martino, Genova, Italy., Bas R; Department of Medical Oncology, Universite Paris Cité, Institut Curie, Paris, France., Kim HJ; Division of Breast Surgery, Department of Surgery, Asan Medical Center, University of Ulsan College of Medicine, Seoul, South Korea., Di Meglio A; Cancer Survivorship Group, INSERM U981, Gustave Roussy, Villejuif, France., Bernstein Molho R; Susanne Levy Gertner Oncogenetics Unit, The Danek Gertner Institute of Human Genetics, Chaim Sheba Medical Center affiliated to Tel Aviv University, Tel Hashomer, Israel., Linn SC; Department of Medical Oncology, Netherlands Cancer Institute (NKI), Amsterdam, The Netherlands.; Department of Pathology, University Medical Center Utrecht, Utrecht, The Netherlands., Pogoda K; Department of Breast Cancer and Reconstructive Surgery, Maria Sklodowska-Curie National Research Institute of Oncology, Warsaw, Poland., Carrasco E; Hereditary Cancer Genetics Unit, Medical oncology Department, Vall d´Hebron University Hospital, Vall d´Hebron Institute of Oncology (VHIO), Barcelona, Spain., Punie K; Department of General Medical Oncology and Multidisciplinary Breast Center, Leuven Cancer Institute, University Hospitals Leuven, Leuven, Belgium., Agostinetto E; Institut Jules Bordet and l'Université Libre de Bruxelles (U.L.B.), Hôpital Universitaire de Bruxelles (HUB), Brussels, Belgium., Lopetegui-Lia N; Department of Medical Oncology, Cleveland Clinic Taussig Cancer Institute, Cleveland, Ohio, USA., Phillips KA; Department of Medical Oncology, Peter MacCallum Cancer Centre, Melbourne, Victoria, Australia.; Sir Peter MacCallum Department of Oncology, The University of Melbourne, Melbourne, Victoria, Australia.; Centre for Epidemiology and Biostatistics, School of Population and Global Health, The University of Melbourne, Melbourne, Victoria, Australia., Toss A; Department of Oncology and Haematology, Azienda Ospedaliero-Universitaria di Modena, Modena, Italy.; Division of Oncology, Department of Medical and Surgical Sciences, University of Modena and Reggio Emilia, Modena, Italy., Rousset-Jablonski C; Department of Surgery, Leon Berard Cancer Center, Lyon, France.; Unité INSERM U1290, Université Claude Bernard Lyon 1, Lyon, France.; Hopital Femme Mère Enfant, Hospice civils de Lyon, Bron, France., Acheritogaray M; Department of Gynecology, Cote Basque Hospital Center, Bayonne, France., Ferrari A; Hereditary Breast and Ovarian Cancer (HBOC) Unit and General Surgery 3 - Senology, Breast Cancer Center, Fondazione IRCCS Policlinico San Matteo, Pavia, Italy.; University of Pavia, Pavia, Italy., Paluch-Shimon S; Sharett institute of oncology, Hadassah University Hospital & Faculty of Medicine, Hebrew University, Jerusalem, Israel., Fruscio R; UO Gynecology, Department of Medicine and Surgery, University of Milan-Bicocca, IRCCS San Gerardo dei Tintori, Monza, Italy., Cui W; Department of Medical Oncology, Peter MacCallum Cancer Centre, Melbourne, Victoria, Australia.; Sir Peter MacCallum Department of Oncology, The University of Melbourne, Melbourne, Victoria, Australia., Wong SM; Stroll Cancer Prevention Centre, Jewish General Hospital, and McGill University Medical School, Montreal, Quebec, Canada., Vernieri C; Medical Oncology Department, Breast Unit, Fondazione IRCCS Istituto Nazionale dei Tumori, Milano, Italy.; Oncology and Hematology-Oncology Department, University of Milan, Milano, Italy., Dieci MV; Dipartimento di Scienze Chirurgiche, Oncologiche e Gastroenterologiche, Università di Padova, Padova, Italy.; Oncologia 2, Istituto Oncologico Veneto IRCCS, Padova, Italy., Matikas A; Department of Oncology/Pathology, Karolinska Institute and Breast Center, Karolinska University Hospital, Stockholm, Sweden., Rozenblit M; Medical Oncology, Yale University, New Haven, Connecticut, USA., Villarreal-Garza C; Breast Cancer Center, Hospital Zambrano Hellion - TecSalud, Tecnologico de Monterrey, Monterrey, Mexico., De Marchis L; Division of Medical Oncology, Department of Radiological, Oncological and Pathological Sciences, Sapienza University of Rome, Rome, Italy.; Medical Oncology Department of Hematology, Oncology, Dermatology, Umberto 1 University Hospital, Rome, Italy., Puglisi F; Department of Medical Oncology, Centro di Riferimento Oncologico di Aviano (CRO) IRCCS, Aviano, Italy.; Department of Medicine, University of Udine, Udine, Italy., Vasconcelos de Matos L; Breast Cancer Unit, Champalimaud Clinical Center, Champalimaud Foundation, Lisbon, Portugal., Mariño M; Hospital Universitari Son Espases Palma, Palma, Spain., Teixeira L; Department of Senology, Université Paris Cité, Assistance Publique-Hôpitaux de Paris, Saint Louis University Hospital, Paris, France., Graffeo R; Oncology Institute of Southern Switzerland, EOC-IOSI, Bellinzona, Switzerland., Rognone A; Department of Oncology, IRCCS Ospedale San Raffaele, Milano, Italy., Chirco A; Medical Oncology Unit, ASST Papa Giovanni XXIII, Bergamo, Italy., Antone N; Institute of Oncology 'Ion Chiricuta', Cluj-Napoca, Romania., Abdou Y; University of North Carolina - Lineberger Comprehensive Cancer Center, Chapel Hill, North Carolina, USA., Marhold M; Division of Oncology, Department of Medicine I, Medical University of Vienna, Vienna, Austria., Božović-Spasojević I; Institute for Oncology and Radiology of Serbia, University of Belgrade, Faculty of Medicine, Belgrade, Serbia., Cortés Salgado A; Medical Oncology Department, Hospital Universitario Ramón y Cajal, Madrid, Spain., Carmisciano L; Department of Clinical and Experimental Medicine, University of Pisa, Pisa, Italy., Bruzzone M; U.O. Epidemiologia Clinica, IRCCS Ospedale Policlinico San Martino, Genova, Italy., Curigliano G; Early Drug Development for Innovative Therapies Division, IRCCS European Institute of Oncology (IEO), Milan, Italy.; Department of Oncology and Hemato-Oncology, University of Milan, Milan, Italy., Prat A; Translational Genomics and Targeted Therapies in Solid Tumors group, August Pi i Sunyer Biomedical Research Institute (IDIBAPS), Barcelona, Spain.; Department of Medicine and Health Sciences, University of Barcelona, Barcelona, Spain.; Institute of Cancer and Blood Disorders, Hospital Clinic of Barcelona, Barcelona, Spain.; Reveal Genomics, Barcelona, Spain.; Institute of Oncology (IOB)-Hospital Quirón Salud, Barcelona, Spain., Lambertini M; Department of Internal Medicine and Medical Specialties (DiMI), School of Medicine, University of Genova, Genova, Italy.; Department of Medical Oncology, U.O. Clinica di Oncologia Medica, IRCCS Ospedale Policlinico San Martino, Genova, Italy.

المصدر: Cancer [Cancer] 2024 May 16. Date of Electronic Publication: 2024 May 16.

نوع المنشور: Journal Article

بيانات الدورية: Publisher: Wiley Country of Publication: United States NLM ID: 0374236 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1097-0142 (Electronic) Linking ISSN: 0008543X NLM ISO Abbreviation: Cancer Subsets: MEDLINE

المؤلفون: Schettini F; Translational Genomics and Targeted Therapies in Solid Tumors Group, August Pi I Sunyer Biomedical Research Institute (IDIBAPS), Barcelona, Spain.; Medical Oncology Department, Hospital Clinic of Barcelona, Barcelona, Spain.; Faculty of Medicine and Health Sciences, University of Barcelona, Barcelona, Spain., Palleschi M; Department of Medical Oncology, IRCCS Istituto Romagnolo per lo Studio dei Tumori (IRST) 'Dino Amadori,' Meldola, Italy., Mannozzi F; Unit of Biostatistics and Clinical Trials, IRCCS Istituto Romagnolo per lo Studio dei Tumori (IRST) 'Dino Amadori,' Meldola, Italy., Brasó-Maristany F; Translational Genomics and Targeted Therapies in Solid Tumors Group, August Pi I Sunyer Biomedical Research Institute (IDIBAPS), Barcelona, Spain., Cecconetto L; Department of Medical Oncology, IRCCS Istituto Romagnolo per lo Studio dei Tumori (IRST) 'Dino Amadori,' Meldola, Italy., Galván P; Translational Genomics and Targeted Therapies in Solid Tumors Group, August Pi I Sunyer Biomedical Research Institute (IDIBAPS), Barcelona, Spain., Mariotti M; Department of Medical Oncology, IRCCS Istituto Romagnolo per lo Studio dei Tumori (IRST) 'Dino Amadori,' Meldola, Italy., Ferrari A; UO Medicina Oncologia, Ospedale Ramazzini, Azienda USL di Modena, Carpi, Italy., Scarpi E; Unit of Biostatistics and Clinical Trials, IRCCS Istituto Romagnolo per lo Studio dei Tumori (IRST) 'Dino Amadori,' Meldola, Italy., Miserocchi A; Unit of Biostatistics and Clinical Trials, IRCCS Istituto Romagnolo per lo Studio dei Tumori (IRST) 'Dino Amadori,' Meldola, Italy., Nanni O; Unit of Biostatistics and Clinical Trials, IRCCS Istituto Romagnolo per lo Studio dei Tumori (IRST) 'Dino Amadori,' Meldola, Italy., Sanfeliu E; Medical Oncology Department, Hospital Clinic of Barcelona, Barcelona, Spain.; Department of Pathology, Biomedical Diagnostic Center, Hospital Clinic of Barcelona, Barcelona, Spain., Prat A; Translational Genomics and Targeted Therapies in Solid Tumors Group, August Pi I Sunyer Biomedical Research Institute (IDIBAPS), Barcelona, Spain.; Faculty of Medicine and Health Sciences, University of Barcelona, Barcelona, Spain.; Cancer Institute and Blood Diseases, Hospital Clínic of Barcelona, Barcelona, Spain.; Breast Cancer Unit, Institute of Oncology Barcelona (IOB), Quirónsalud, Barcelona, Spain.; Reveal Genomics, Barcelona, Spain., Rocca A; Department of Medical, Surgical and Health Sciences, University of Trieste, Trieste, Italy., De Giorgi U; Department of Medical Oncology, IRCCS Istituto Romagnolo per lo Studio dei Tumori (IRST) 'Dino Amadori,' Meldola, Italy.

المصدر: The oncologist [Oncologist] 2024 May 03; Vol. 29 (5), pp. e622-e634.

نوع المنشور: Journal Article; Clinical Trial, Phase II; Randomized Controlled Trial; Research Support, Non-U.S. Gov't

بيانات الدورية: Publisher: Oxford University Press Country of Publication: England NLM ID: 9607837 Publication Model: Print Cited Medium: Internet ISSN: 1549-490X (Electronic) Linking ISSN: 10837159 NLM ISO Abbreviation: Oncologist Subsets: MEDLINE

مواضيع طبية MeSH: Breast Neoplasms*/drug therapy , Breast Neoplasms*/pathology , Cyclin-Dependent Kinase 4*/antagonists & inhibitors , Cyclin-Dependent Kinase 6*/antagonists & inhibitors , Biomarkers, Tumor*/metabolism , Receptor, ErbB-2*/metabolism, Humans ; Female ; Middle Aged ; Aged ; Adult ; Protein Kinase Inhibitors/therapeutic use ; Protein Kinase Inhibitors/pharmacology ; Antineoplastic Combined Chemotherapy Protocols/therapeutic use ; Antineoplastic Combined Chemotherapy Protocols/pharmacology ; Receptors, Estrogen/metabolism ; Receptors, Progesterone/metabolism

المؤلفون: Gebhart G; Nuclear Medicine Department, Institut Jules Bordet, Hôpital Universitaire de Bruxelles, Université Libre de Bruxelles, Brussels, Belgium., Keyaerts M; Vrije Universiteit Brussel, Brussels, Belgium., Guiot T; Nuclear Medicine Department, Institut Jules Bordet, Hôpital Universitaire de Bruxelles, Université Libre de Bruxelles, Brussels, Belgium., Flamen P; Nuclear Medicine Department, Institut Jules Bordet, Hôpital Universitaire de Bruxelles, Université Libre de Bruxelles, Brussels, Belgium., Ruiz-Borrego M; Hospital Universitario Virgen del Rocío, Seville, Spain., Stradella A; Medical Oncology Department, Institut Català D'Oncologia, L'Hospitalet de Llobregat, Barcelona, Spain., Bermejo B; Hospital Clínico Universitario de Valencia, Valencia, Spain., Escriva-de-Romani S; Breast Cancer Group, Medical Oncology Department, Vall d'Hebron Institute of Oncology, Vall d'Hebron University Hospital, Barcelona, Spain., Calvo Martínez L; Medical Oncology Department, Complejo Hospitalario Universitario A Coruña, A Coruña, Spain., Ribelles N; UGC Oncología Intercentros, Hospitales Universitarios Regional y Virgen de la Victoria de Málaga, Instituto de Investigaciones Biomédicas de Málaga, Málaga, Spain., Fernandez-Abad M; Medical Oncology Department, Ramón y Cajal Hospital, Madrid, Spain.; Alcala de Henares Medical University, Alcala de Henares, Madrid., Albacar C; Hospital Universitari Sant Joan de Reus, Reus, Spain., Colleoni M; IEO, European Institute of Oncology IRCCS, Milan, Italy., Garrigos L; Hospital Universitari Dexeus, Barcelona, Spain., Atienza de Frutos M; Faculty of Biomedical and Health Sciences, Department of Medicine, Universidad Europea de Madrid, Madrid, Spain., Dalenc F; Institut Claudius Regaud, IUCT-Oncopole, Toulouse Cancer Research Centre, INSERM, Toulouse, France., Prat A; Department of Medical Oncology, Hospital Clinic of Barcelona, Barcelona, Spain.; Translational Genomics and Targeted Therapies Group, IDIBAPS, Barcelona, Spain.; Department of Medicine, University of Barcelona, Barcelona, Spain., Marmé F; Medical Faculty Mannheim Heidelberg University, University Hospital Mannheim, Heidelberg, Germany., Schmid P; Barts Experimental Cancer Medicine Centre, Barts Cancer Institute, Queen Mary University of London, London, United Kingdom.; Barts Hospital NHS Trust, London, United Kingdom., Kerrou K; Nuclear Medicine and PET Center Department, Tenon Hospital IUC-UPMC, APHP, Sorbonne University, Paris, France., Braga S; Hospital Vila Franca de Xira and Hospitals CUF Institute José de Mello Saúde, Lisbon, Portugal., Gener P; Medica Scientia Innovation Research, Barcelona, Spain., Sampayo-Cordero M; Medica Scientia Innovation Research, Barcelona, Spain., Cortés J; Medica Scientia Innovation Research, Barcelona, Spain.; International Breast Cancer Center, Quiron Group, Pangaea Oncology, Barcelona, Spain.; Faculty of Biomedical and Health Sciences, Department of Medicine, Universidad Europea de Madrid, Madrid, Spain., Pérez-García JM; Medica Scientia Innovation Research, Barcelona, Spain.; International Breast Cancer Center, Quiron Group, Pangaea Oncology, Barcelona, Spain., Llombart-Cussac A; Medica Scientia Innovation Research, Barcelona, Spain; antonio.llombart@maj3.health.; Hospital Universitario Arnau de Vilanova, Universidad Católica de Valencia, Valencia, Spain.

المصدر: Journal of nuclear medicine : official publication, Society of Nuclear Medicine [J Nucl Med] 2024 May 01; Vol. 65 (5), pp. 708-713. Date of Electronic Publication: 2024 May 01.

نوع المنشور: Journal Article; Research Support, Non-U.S. Gov't

بيانات الدورية: Publisher: Society of Nuclear Medicine Country of Publication: United States NLM ID: 0217410 Publication Model: Electronic Cited Medium: Internet ISSN: 1535-5667 (Electronic) Linking ISSN: 01615505 NLM ISO Abbreviation: J Nucl Med Subsets: MEDLINE

مواضيع طبية MeSH: Breast Neoplasms*/diagnostic imaging , Breast Neoplasms*/metabolism , Breast Neoplasms*/drug therapy , Positron Emission Tomography Computed Tomography* , Receptor, ErbB-2*/metabolism, Humans ; Female ; Middle Aged ; Fluorodeoxyglucose F18 ; Aged ; Adult ; Treatment Outcome ; Trastuzumab/therapeutic use ; Antibodies, Monoclonal, Humanized/therapeutic use

المؤلفون: Pérez-García JM; International Breast Cancer Center (IBCC), Pangaea Oncology, Quiron Group, Barcelona 08022, Spain; Medica Scientia Innovation Research (MEDSIR), Barcelona, Spain., Cortés J; International Breast Cancer Center (IBCC), Pangaea Oncology, Quiron Group, Barcelona 08022, Spain; Medica Scientia Innovation Research (MEDSIR), Barcelona, Spain; Department of Medicine, Faculty of Biomedical and Health Sciences, Universidad Europea de Madrid, Madrid, Spain., Ruiz-Borrego M; University Hospital Virgen del Rocío, Sevilla, Spain., Colleoni M; IEO, European Institute of Oncology IRCCS, Milan, Italy., Stradella A; Medical Oncology Department, Institut Català D'Oncologia, L'Hospitalet de Llobregat, Barcelona, Spain., Bermejo B; Medical Oncology, Hospital Clínico Universitario de Valencia, Biomedical Research Institute INCLIVA, Valencia, Spain; Medicine Department, Universidad de Valencia, Spain; Oncology Biomedical Research National Network (CIBERONC-ISCIII), Madrid, Spain., Dalenc F; Oncopole Claudius Regaud- IUCT, Inserm, Department of Medical Oncology, Toulouse, France., Escrivá-de-Romaní S; Medical Oncology Department, Breast Cancer Group, Vall d'Hebron University Hospital, Vall d'Hebron Institute of Oncology (VHIO), Barcelona, Spain., Calvo Martínez L; Hospital Universitario A Coruña, A Coruña, Spain., Ribelles N; UGC Oncología Intercentros, Hospitales Universitarios Regional y Virgen de la Victoria de Málaga, Instituto de Investigaciones Biomédicas de Málaga (IBIMA), Málaga, Spain., Marmé F; University Hospital Mannheim; Medical Faculty Mannheim, Heidelberg University, Mannheim, Germany., Cortés A; University Hospital Ramón y Cajal, Madrid, Spain., Albacar C; Hospital Universitari Sant Joan de Reus, Reus, Spain., Gebhart G; Department of Nuclear Medicine, Institut Jules Bordet, Hôpital Universitaire de Bruxelles (HUB), Université Libre de Bruxelles (ULB), Brussels, Belgium., Prat A; Department of Medical Oncology, Hospital Clinic of Barcelona, Barcelona, Spain; Translational Genomics and Targeted Therapies Group, IDIBAPS, Barcelona, Spain; Department of Medicine, University of Barcelona, Barcelona, Spain., Kerrou K; APHP, Tenon Hospital IUC-UPMC, Nuclear Medicine and PET Center Department, Sorbonne University, Paris, France; INSERM U938 (Cancer Biology and Therapeutics), Paris, France., Schmid P; Barts Experimental Cancer Medicine Centre, Barts Cancer Institute, Queen Mary University of London, UK; Barts Hospital NHS Trust, London, UK., Braga S; Unidade de Mama, Instituto CUF de Oncologia, Lisbon, Portugal; NOVA Medical School, Faculdade de Ciências Médicas, Universidade Nova de Lisboa, Lisbon, Portugal., Di Cosimo S; Department of Advanced Diagnostics, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy., Gion M; University Hospital Ramón y Cajal, Madrid, Spain., Antonarelli G; Division of New Drugs and Early Drug Development for Innovative Therapies, European Institute of Oncology, IRCCS, Milan, Italy; Department of Oncology and Hemato-Oncology (DIPO), University of Milan, Milan, Italy., Popa C; Medica Scientia Innovation Research (MEDSIR), Barcelona, Spain., Szostak E; Medica Scientia Innovation Research (MEDSIR), Barcelona, Spain., Alcalá-López D; Medica Scientia Innovation Research (MEDSIR), Barcelona, Spain., Gener P; Medica Scientia Innovation Research (MEDSIR), Barcelona, Spain., Rodríguez-Morató J; Medica Scientia Innovation Research (MEDSIR), Barcelona, Spain., Mina L; Medica Scientia Innovation Research (MEDSIR), Barcelona, Spain., Sampayo-Cordero M; Medica Scientia Innovation Research (MEDSIR), Barcelona, Spain., Llombart-Cussac A; Medica Scientia Innovation Research (MEDSIR), Barcelona, Spain; Hospital Arnau de Vilanova, Universidad Católica de Valencia, Valencia, Spain. Electronic address: antonio.llombart@maj3.health.

مؤلفون مشاركون: PHERGain Trial Investigators

المصدر: Lancet (London, England) [Lancet] 2024 Apr 27; Vol. 403 (10437), pp. 1649-1659. Date of Electronic Publication: 2024 Apr 03.

نوع المنشور: Journal Article; Clinical Trial, Phase II; Randomized Controlled Trial; Research Support, Non-U.S. Gov't; Multicenter Study

بيانات الدورية: Publisher: Elsevier Country of Publication: England NLM ID: 2985213R Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1474-547X (Electronic) Linking ISSN: 01406736 NLM ISO Abbreviation: Lancet Subsets: MEDLINE

مواضيع طبية MeSH: Breast Neoplasms*/drug therapy , Breast Neoplasms*/pathology , Fluorodeoxyglucose F18* , Trastuzumab*/therapeutic use , Trastuzumab*/administration & dosage , Receptor, ErbB-2*/metabolism , Docetaxel*/therapeutic use , Docetaxel*/administration & dosage , Antineoplastic Combined Chemotherapy Protocols*/therapeutic use , Antibodies, Monoclonal, Humanized*/therapeutic use , Antibodies, Monoclonal, Humanized*/administration & dosage , Antibodies, Monoclonal, Humanized*/adverse effects, Humans ; Female ; Middle Aged ; Adult ; Disease-Free Survival ; Aged ; Positron-Emission Tomography/methods ; Carboplatin/administration & dosage ; Carboplatin/therapeutic use ; Radiopharmaceuticals